@FierceBiotech: SEC hunting down traders who made a quick killing on Onyx shares. Report | Follow @FierceBiotech
@JohnCFierce: Top Novartis blockbuster prospect whips Enbrel in psoriasis showdown. News | Follow @JohnCFierce
@RyanMFierce: For those of you who remember Son of Lantus, watch out for Lantus' fraternal (not identical) twin from Lilly and Boehringer. | Follow @RyanMFierce
@EmilyMFierce: Cholera is altering the human genome. Story | Follow @EmilyMFierce
> Eli Lilly ($LLY) and Boehringer Ingelheim announced that their marketing authorization application for LY2963016, a lookalike of Sanofi's ($SNY) Lantus, has been accepted for review by the
> Novartis ($NVS) and India's BioE are partnering on two new vaccines for typhoid and paratyphoid fevers. Story
> AstraZeneca ($AZN) will work with the Sarah Cannon Research Institute on new cancer drugs. Story
> BioDelivery Sciences International ($BDSI) has landed a $20 million loan. Release
> Astex Pharmaceuticals ($ASTX) says it will file an IND for ASTX727, an oral hypomethylating agent, in the fourth quarter of this year. Release
Medical Device News
@FierceMedDev: Roche chases FDA cancer indication for HPV diagnostic. Story | Follow @FierceMedDev
@MarkHFierce: Duke has found early promise with a blood Dx that predicts aspirin treatment success. Report | Follow @MarkHFierce
@DamianFierce: Patient lawsuits mount as India tries to crack down on unethical clinical trials. Item | Follow @DamianFierce
> Nikon mulls entry into medical devices business. Story
> Crescendo Bioscience achieves Medicare coverage for RA Dx. News
Pharma News
@FiercePharma: Cost watchdogs veto Novartis breast cancer med Afinitor. NICE says "disappointed" data isn't stronger. News | Follow @FiercePharma
> Vivus, FMC both tout proxy advisers' support for board nominees. Article
> Medicare won't pay for Eli Lilly Alzheimer's agent. News
> Roche bids for broad use of HPV test to screen for cervical cancer. Story
> Cost watchdogs veto Novartis breast cancer med Afinitor. More
> Vivus, FMC both tout proxy advisers' support for board nominees. Article
CRO News
> Report: Academia could better use CROs for early research. News
> Lawsuits mount as India pushes trial reforms. Article
> CRO Blue Sky taps new CEO amid growth. Story
> Parexel teams with Rutgers for clinical trials. More
> CROs shift as early-phase demand dries up. News
Biotech IT News
> Report: Pharma execs warm to med reminder apps. News
> GE, Accenture back analytics provider in $20M financing. Article
> Bioinformatics gives U. Wisconsin team an 'edge' in cystic fibrosis study. Story
> AstraZeneca snaps up drug-discovery software from Cambridge startup. More
> Facebook, Twitter bolster Canadian biotech's research of Crohn's therapy. News
And Finally… A new study concludes that doctors who carefully individualize treatment for diabetes in patients over the age of 70 can achieve significantly better outcomes. Story